Sprycel to undergo pricing readjustments

Published: 2008-03-12 07:00:00

Updated: 2008-03-12 07:00:00

The government plans to review the pricing feasibility of BMS's Sprycel (dasatinib), an oral inhibitor of multiple tyrosine kinases, at the meeting of an insurance price coordination committee to be first held during the second week of this month.

The price coordination committee, under the um...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK